The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SLP | -48.55% | -74.34% | -23.82% | +1,543% |
| S&P | +14.5% | +93.32% | +14.09% | +654% |
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.
Investors weren't happy about hiccups that pressured fiscal third-quarter revenue.
The company continues to anticipate swift, double-digit revenue growth over the next several quarters.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $20.36M | 9.8% |
| Gross Profit | $13.03M | -1.7% |
| Gross Margin | 64.00% | -7.5% |
| Market Cap | $640.43M | -33.6% |
| Market Cap / Employee | $2.59M | 0.0% |
| Employees | 247 | 0.0% |
| Net Income | -$67.32M | -2245.9% |
| EBITDA | $5.30M | 68.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $26.95M | -75.3% |
| Accounts Receivable | $18.98M | 37.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.45M | -12.1% |
| Short Term Debt | $0.27M | -34.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.64% | -43.8% |
| Return On Invested Capital | 6.01% | -3.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $7.85M | 41.0% |
| Operating Free Cash Flow | $8.14M | 43.3% |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 101.64 | 74.01 | 78.62 | 81.11 | 1.22% |
| Price to Book | 4.01 | 3.49 | 3.15 | 3.38 | -36.69% |
| Price to Sales | 10.38 | 8.65 | 7.48 | 7.97 | -45.86% |
| Price to Tangible Book Value | 5.62 | 23.15 | 18.88 | 17.35 | 131.75% |
| Price to Free Cash Flow TTM | 91.34 | 84.36 | 64.89 | 51.09 | -52.42% |
| Enterprise Value to EBITDA | 670.72 | 233.00 | 111.49 | 115.73 | -58.08% |
| Free Cash Flow Yield | 1.1% | 1.2% | 1.5% | 2.0% | 110.15% |
| Return on Equity | 5.6% | 4.6% | 4.0% | -41.5% | -853.30% |
| Total Debt | $1.01M | $1.32M | $0.80M | $0.72M | -22.02% |
SLP earnings call for the period ending June 30, 2022.
SLP earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
